Onego Bio Revolutionizes Food Industry with Animal-Free Egg Protein
April 4, 2024, 3:51 pm
Onego Bio, a US-Finnish biotech company, has secured a groundbreaking $40 million in Series A funding to propel the commercialization of its innovative animal-free egg protein. The company's Bioalbumen® is a game-changer in the food industry, offering a sustainable and high-quality alternative to traditional egg production methods.
With precision fermentation technology at its core, Onego Bio's Bioalbumen® is bioidentical to the major egg white protein ovalbumin, boasting a neutral taste and exceptional nutritional profile. This revolutionary ingredient contains all essential amino acids, scores a perfect 1.0 on the protein digestibility scale, and packs over 90g of protein per 100g.
Ideal for a wide range of food applications, Bioalbumen® is set to transform the way we think about eggs in products like cakes, mayonnaise, batters, and nougat fillings. The company's collaboration with over 25 prominent consumer packaged goods companies underscores the widespread appeal and versatility of this cutting-edge ingredient.
Onego Bio's commitment to sustainability is evident in its efforts to reduce greenhouse gas emissions by 90% and land use by 95% compared to conventional egg production methods. By offering a safe, reliable, and environmentally friendly alternative, the company is poised to make a significant impact on the food industry.
The recognition and support from investors like NordicNinja, Tesi, EIT Food, and Agronomics, as well as the Finnish government association Business Finland, highlight the industry's confidence in Onego Bio's vision and technology. With plans to secure GRAS status and FDA approval, the company is well-positioned to lead the way in transforming the food system.
As Onego Bio expands its reach into North America, Europe, South America, and Asia, the potential for widespread adoption of Bioalbumen® is immense. With a focus on scalability, market entry acceleration, and strategic partnerships, the company is on track to revolutionize the $330 billion egg market and drive systemic change in the global food industry.
In the words of Maija Itkonen, co-founder and CEO of Onego Bio, the company's mission is clear: to deliver a revolutionary ingredient that offers unmatched functionality, taste, and texture. With a passionate team and visionary investors by their side, Onego Bio is poised to reshape the future of food with its innovative animal-free egg protein.
With precision fermentation technology at its core, Onego Bio's Bioalbumen® is bioidentical to the major egg white protein ovalbumin, boasting a neutral taste and exceptional nutritional profile. This revolutionary ingredient contains all essential amino acids, scores a perfect 1.0 on the protein digestibility scale, and packs over 90g of protein per 100g.
Ideal for a wide range of food applications, Bioalbumen® is set to transform the way we think about eggs in products like cakes, mayonnaise, batters, and nougat fillings. The company's collaboration with over 25 prominent consumer packaged goods companies underscores the widespread appeal and versatility of this cutting-edge ingredient.
Onego Bio's commitment to sustainability is evident in its efforts to reduce greenhouse gas emissions by 90% and land use by 95% compared to conventional egg production methods. By offering a safe, reliable, and environmentally friendly alternative, the company is poised to make a significant impact on the food industry.
The recognition and support from investors like NordicNinja, Tesi, EIT Food, and Agronomics, as well as the Finnish government association Business Finland, highlight the industry's confidence in Onego Bio's vision and technology. With plans to secure GRAS status and FDA approval, the company is well-positioned to lead the way in transforming the food system.
As Onego Bio expands its reach into North America, Europe, South America, and Asia, the potential for widespread adoption of Bioalbumen® is immense. With a focus on scalability, market entry acceleration, and strategic partnerships, the company is on track to revolutionize the $330 billion egg market and drive systemic change in the global food industry.
In the words of Maija Itkonen, co-founder and CEO of Onego Bio, the company's mission is clear: to deliver a revolutionary ingredient that offers unmatched functionality, taste, and texture. With a passionate team and visionary investors by their side, Onego Bio is poised to reshape the future of food with its innovative animal-free egg protein.